[1]肖琳琳,蔡丽芳.重组人血管内皮抑制素与顺铂交替灌注治疗恶性胸腹腔积液近期疗效观察[J].新乡医学院学报,2016,33(7):632-635.[doi:10.7683/xxyxyxb.2016.07.023]
 XIAO Lin-lin,CAI Li-fang.Short-term effect of recombinant human endostatin and cisplatin alternating perfusion in treatment of malignant pleural effusion or seroperitoneum[J].Journal of Xinxiang Medical University,2016,33(7):632-635.[doi:10.7683/xxyxyxb.2016.07.023]
点击复制

重组人血管内皮抑制素与顺铂交替灌注治疗恶性胸腹腔积液近期疗效观察
分享到:

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
33
期数:
2016年7
页码:
632-635
栏目:
临床研究
出版日期:
2016-07-05

文章信息/Info

Title:
Short-term effect of recombinant human endostatin and cisplatin alternating perfusion in treatment of malignant pleural effusion or seroperitoneum
作者:
肖琳琳蔡丽芳
(莆田市第一医院肿瘤内科,福建 莆田 351100)
Author(s):
XIAO Lin-linCAI Li-fang
(Department of Oncology,the First Hospital of Putian City,Putian 351100,Fujian Province,China)
关键词:
恶性胸腔积液恶性腹腔积液重组人血管内皮抑制素顺铂灌注疗法
Keywords:
malignant pleural effusionmalignant seroperitoneumrecombinant human endostatincisplatininfusion therapy
分类号:
R730.6
DOI:
10.7683/xxyxyxb.2016.07.023
文献标志码:
A
摘要:
目的 探讨重组人血管内皮抑制素与顺铂交替灌注治疗恶性胸、腹腔积液的近期疗效。方法 选取2012年2月至2014年2月莆田市第一医院收治的晚期恶性肿瘤伴恶性胸、腹腔积液患者86例,根据治疗方法分为对照组和观察组,每组43例。治疗前所有患者经皮穿刺置管引流胸、腹腔积液,观察组患者给予顺铂60 mg·m-2+生理盐水40 mL腹腔灌注,第1~3天;重组人血管内皮抑制素60 mg+生理盐水10 mL腹腔灌注,第1、4、7天;对照组患者仅给予顺铂60 mg·m-2+生理盐水40 mL腹腔灌注,第1~3天;3周为1个周期。治疗2个周期后评估患者近期疗效及不良反应,比较2组患者功能状态Karnofsky评分和生活质量(QOL)评分,采用酶联免疫吸附试验检测患者积液中白细胞介素-10(IL-10)、肿瘤坏死因子-α(TNF-α)、干扰素-γ(IFN-γ)水平;门诊随访1 a,记录2组患者的生存率。结果 观察组和对照组患者治疗总有效率分别为79.07%(34/43)和51.16%(22/43),观察组患者治疗总有效率显著高于对照组(P<0.05)。治疗前2组患者积液中IL-10、TNF-α、IFN-γ水平比较差异均无统计学意义(P>0.05);与治疗前比较,治疗后2组患者IL-10水平显著降低,TNF-α、IFN-γ水平显著升高(P<0.05);治疗后观察组患者IL-10水平显著低于对照组(P<0.05),TNF-α、IFN-γ水平显著高于对照组(P<0.05)。治疗前2组患者Karnofsky评分、QOL评分比较差异均无统计学意义(P>0.05);治疗后2组患者Karnofsky评分、QOL评分均显著高于治疗前(P<0.05);治疗后观察组患者Karnofsky评分、QOL评分显著高于对照组(P<0.05)。观察组和对照组患者1 a生存率分别为55.81%(24/43)和32.56%(14/43),观察组患者1 a生存率显著高于对照组(P<0.05)。治疗期间2组患者Ⅱ~Ⅲ级白细胞减少、皮肤灼伤、血小板减少发生率比较差异均无统计学意义(P>0.05);观察组患者Ⅱ~Ⅲ级胃肠道反应发生率显著高于对照组(P<0.05),但经对症处理后均缓解,未影响临床治疗。结论 重组人血管内皮抑制素与顺铂交替灌注治疗恶性胸、腹腔积液近期疗效确切,能够提高患者生活质量。
Abstract:
Objective To investigate the short-term effect of recombinant human endostatin and cisplatin alternating perfusion in treatment of malignant pleural effusion or seroperitoneum.Methods Eighty-six patients with advanced malignant tumors complicated with malignant pleural effusion or seroperitoneum were selected in the First Hospital of Putian City from February 2012 to February 2014.The patients were divided into observation group and control group according to therapeutic method,forty-three patients in each group.All patients were performed with percutaneous catheter drainage of pleural and peritoneal effusion before treatment.The patients in observation group were treated with cisplatin 60 mg·m-2 and normal saline 40 mL by intraabdominal perfusion from the 1st day to 3rd day;and the patients in observation group were treated with recombinant human endostatin 60 mg and normal saline 10 mL by intraabdominal perfusion on the 1st,4th and 7th day.The patients in control group were treated with cisplatin 60 mg·m-2 and normal saline 40 mL by intraabdominal perfusion from the 1st day to 3rd day.Three weeks was a treatment cycle.The short-term effect and adverse reaction of patients were evaluated after two treatment cycle.The Karnofsky score of functional status and quality of life(QOL) score were compared between the two groups.The levels of interleukin-10(IL-10),tumor necrosis factor-α(TNF-α) and interferon-γ(IFN-γ) in effusion were detected by enzyme linked immunosorbent assay.All the patients were followed up for one year,and the survival rate of the patients in the two groups was recorded.Results The total effective rate in observation group and control group was 79.07%(34/43) and 51.16%(22/43),the total effective rate in observation group was significantly higher than that in control group(P<0.05).There was no significant difference in the levels of IL-10,TNF-α and IFN-γ in effusion between the two groups before treatment (P>0.05).Compared with control group,the IL-10 level was significantly decreased(P<0.05),and the levels of TNF-α and IFN-γ were significantly increased in the two groups after treatment(P<0.05).After treatment,the level of IL-10 in observation group was significantly lower than that in control group (P<0.05),the levels of TNF-α and IFN-γ were significantly higher than those in control group(P<0.05).There was no significant difference in Karnofsky score and QOL score between the two groups before treatment(P>0.05).The Karnofsky score and QOL score after treatment were significantly higher than those before treatment in the two groups(P<0.05).The Karnofsky score and QOL score in observation group were significantly higher than those in control groups(P<0.05).The one-year survival rate in observation group and control group was 55.81%(24/43) and 32.56%(14/43) respectively,the one-year survival rate in observation group was significantly higher than that in control group(P<0.05).There was no significant difference in the incidences of grade Ⅱ-Ⅲ leucopenia,skin burn and thrombocytopenia between the two groups during the treatment period (P>0.05).The incidence of gastrointestinal tract reaction(grade Ⅱ-Ⅲ) in observation group was significantly higher than that in control group(P<0.05),but the gastrointestinal tract reaction relieved after symptomatic treatment,and did not affect the clinical treatment.Conclusion Recombinant human endostatin and cisplatin alternating perfusion in treatment of malignant pleural effusion or seroperitoneum can obtain preonunced short-term effect,and can improve the QOL of patients.

参考文献/References:

[1] 王琼,袁明,王南瑶,等.重组人血管内皮抑制素联合热疗治疗恶性胸腹腔积液的临床观察[J].实用临床医药杂志,2011,15(13):26-28.
[2] 汤钊猷.现代肿瘤学[M].2版.上海:复旦大学出版社,2000:483.
[3] 林榕生,萧国材,吴楚海,等.胸腹腔化疗联合沙培林体腔灌注治疗恶性胸腹腔积液的临床疗效[J].山东医药,2012,52(41):56-57.
[4] 代新幼,曾学富,黄舒,等.复方苦参注射液联合顺铂热灌注治疗恶性胸腹腔积液近期疗效分析[J].肿瘤研究与临床,2012,24(7):486-487
[5] 郑立平,夏立平,许铁峰,等.顺铂、恩度序贯灌注治疗恶性胸腹水的临床疗效及其对血管内皮生长因子的影响[J].实用预防医学,2011,18(8):1494-1496.
[6] 李晓琴,姬发祥,林民哲,等.恩度联合化疗药物治疗恶性胸腹腔积液的临床观察[J].现代肿瘤医学,2012,20(2):388-390.
[7] 蒋建龙,盛友华,何忠惠,等.白细胞介素-2治疗前后恶性胸腹水白细胞抗原DR、淋巴细胞微核含量及T细胞亚型改变的临床研究[J].中国癌症杂志,2010,20(4):261-264.
[8] 赵学涛,杨从容,王坤,等.辐照红细胞输注对围手术期肺癌患者血清IL-10、IL-6、TNF-α及IFN-γ的影响[J].第三军医大学学报,2014,36(6):608-610..
[9] 孙聪聪,李英,田文君,等.骨髓增殖性肿瘤中JAK2V617F突变和TNF-α的表达及两者的相关性研究[J].中国实验血液学杂志,2014,22(4):1022-1026.
[10] 李阳,周欣亮,王玉栋,等.分子靶向药物治疗恶性腹腔积液的研究进展[J].肿瘤防治研究,2013,40(10):1007-1010.
[11] 赵意,蔡开灿,刘德纲,等.恩度联合TP方案对食管癌细胞抑制作用的实验研究[J].实用医学杂志,2012,28(12):1963-1965.

相似文献/References:

[1]花勤良 靳全恒 宋忠民 姚卫华.芬倍舒联合顺氯氨铂治疗恶性胸腔积液[J].新乡医学院学报,2000,17(04):284.
[2]齐 博,赵宝生. 胸腔热灌注治疗恶性胸腔积液疗效观察[J].新乡医学院学报,2015,32(08):759.

更新日期/Last Update: 2016-07-05